The effect of somatostatin and its analogs in the prevention of pancreatic fistula after elective pancreatic surgery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10103831" target="_blank" >RIV/00179906:_____/12:10103831 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/12:43874685 RIV/00216208:11150/12:10103831

Výsledek na webu

<a href="http://www.springerlink.com/content/fg322r4720j311m4/fulltext.pdf" target="_blank" >http://www.springerlink.com/content/fg322r4720j311m4/fulltext.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10353-011-0612-z" target="_blank" >10.1007/s10353-011-0612-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The effect of somatostatin and its analogs in the prevention of pancreatic fistula after elective pancreatic surgery

Popis výsledku v původním jazyce

The prophylactic use of somatostatin and its analogs has been suggested to lower the rate of pancreatic fistula.The aim of this review is to discuss the results of published randomized trials and metaanalyses studying the effect of somatostatin and its analogs. We performed a Medline search for prospective randomized trials, systematic reviews and meta-analyses with regard to the prophylactic use of somatostatin and its analogs. Eleven randomized trials and six meta-analyses were identified. The randomized trials differ in terms of study designs, diagnosis, operative procedures, drug dosage, time of administration, and the pancreatic fistula definition; therefore, it is advisable to carefully interpret the results of the individual randomized trials. The routine administration of somatostatin and its analogs in elective pancreatic surgery cannot be recommended. However, selective administration is advisable in cases which carry significantly higher risk of developing pancreatic fistula

Název v anglickém jazyce

The effect of somatostatin and its analogs in the prevention of pancreatic fistula after elective pancreatic surgery

Popis výsledku anglicky

The prophylactic use of somatostatin and its analogs has been suggested to lower the rate of pancreatic fistula.The aim of this review is to discuss the results of published randomized trials and metaanalyses studying the effect of somatostatin and its analogs. We performed a Medline search for prospective randomized trials, systematic reviews and meta-analyses with regard to the prophylactic use of somatostatin and its analogs. Eleven randomized trials and six meta-analyses were identified. The randomized trials differ in terms of study designs, diagnosis, operative procedures, drug dosage, time of administration, and the pancreatic fistula definition; therefore, it is advisable to carefully interpret the results of the individual randomized trials. The routine administration of somatostatin and its analogs in elective pancreatic surgery cannot be recommended. However, selective administration is advisable in cases which carry significantly higher risk of developing pancreatic fistula

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Surgery-Acta Chirurgica Austriaca

ISSN

1682-8631

e-ISSN

—

Svazek periodika

44

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

10

Strana od-do

99-108

Kód UT WoS článku

000304610000008

EID výsledku v databázi Scopus

—